Bone metastases from hepatocellular carcinoma:clinical features and prognostic factors
BACKGROUND: Bone metastases (BMs) from hepatocellular carcinoma (HCC) is an increasingly common disease in Asia. We assessed the clinical features, prognostic factors, and differences in outcomes related to BMs among patients with different treatments for HCC.METHODS: Forty-three consecutive patient...
Gespeichert in:
| Veröffentlicht in: | Hepatobiliary & pancreatic diseases international 2017-10, Vol.16 (5), p.499-505 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 505 |
|---|---|
| container_issue | 5 |
| container_start_page | 499 |
| container_title | Hepatobiliary & pancreatic diseases international |
| container_volume | 16 |
| creator | Lu, Yang Hu, Jin-Gen Lin, Xiang-Jin Li, Xi-Gong |
| description | BACKGROUND: Bone metastases (BMs) from hepatocellular carcinoma (HCC) is an increasingly common disease in Asia. We assessed the clinical features, prognostic factors, and differences in outcomes related to BMs among patients with different treatments for HCC.METHODS: Forty-three consecutive patients who were diagnosed with BMs from HCC between January 2010 and December2014 were retrospectively enrolled. The clinical features were identified, the impacts of prognostic factors on survival were statistically analyzed, and clinical data were compared.RESULTS: The median patient age was 54 years; 38 patients were male and 5 female. The most common site for BMs was the trunk (69.3%). BMs with extension to the soft tissue were found in 14 patients (32.5%). Most (90.7%) of the lesions were mixed osteolytic and osteoblastic, and most (69.8%) patients presented with multiple BMs. The median survival after BMs diagnosis was 11 months. In multivariate analyses, survival after BM diagnosis was correlated with Karnofsky performance status (P=0.008) and the Child-Pugh classification(P<0.001); BM-free survival was correlated with progression beyond the University of California San Francisco criteria(P<0.001) and treatment of primary tumors (P<0.001). |
| doi_str_mv | 10.1016/S1499-3872(16)60173-X |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_gjgdybzz_z201705007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>7000324551</cqvip_id><wanfj_id>gjgdybzz_z201705007</wanfj_id><els_id>S149938721660173X</els_id><sourcerecordid>gjgdybzz_z201705007</sourcerecordid><originalsourceid>FETCH-LOGICAL-c547t-40642349657a483eb3b162f0a5a9fc63561bc4926db358336aa40fd213fa6fd03</originalsourceid><addsrcrecordid>eNqFkE9P3DAQxX1oBZT2I7SK1AsIpfh_kl4QoBaQkDjQVtysiWMHrxJ7sRMQ--nxsgvXSpbssd7Me_ND6CvBPwgm8viW8KYpWV3RAyIPJSYVK-8-oL337130KaUFxrSuhdxBu7Rumvyme-jfWfCmGM0EKR-TChvDWNybJUxBm2GYB4iFhqidDyP81IPzTsNQWAPTHLMefFcsY-h9SJPThQU9hZg-o48WhmS-bO999Pf3rz_nl-X1zcXV-el1qQWvppJjySnjjRQV8JqZlrVEUotBQGO1ZEKSVvOGyq5lomZMAnBsO0qYBWk7zPbR0WbuE3gLvleLMEefHVW_6LvndrVSK5p5YIFxldUHG3UO_DCbNKnRpfWW4E2YkyJNjpLd6vVgsZHqGFKKxqpldCPEZ0WwWkNXr9DVmq7K1St0dZf7vm0t5nY03XvXG_EsONkITMby6ExUSTvjtelcNHpSXXD_tfi-jXYffP_g8tZvLhXGmFEuBGEvW32f9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1949692680</pqid></control><display><type>article</type><title>Bone metastases from hepatocellular carcinoma:clinical features and prognostic factors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lu, Yang ; Hu, Jin-Gen ; Lin, Xiang-Jin ; Li, Xi-Gong</creator><creatorcontrib>Lu, Yang ; Hu, Jin-Gen ; Lin, Xiang-Jin ; Li, Xi-Gong</creatorcontrib><description>BACKGROUND: Bone metastases (BMs) from hepatocellular carcinoma (HCC) is an increasingly common disease in Asia. We assessed the clinical features, prognostic factors, and differences in outcomes related to BMs among patients with different treatments for HCC.METHODS: Forty-three consecutive patients who were diagnosed with BMs from HCC between January 2010 and December2014 were retrospectively enrolled. The clinical features were identified, the impacts of prognostic factors on survival were statistically analyzed, and clinical data were compared.RESULTS: The median patient age was 54 years; 38 patients were male and 5 female. The most common site for BMs was the trunk (69.3%). BMs with extension to the soft tissue were found in 14 patients (32.5%). Most (90.7%) of the lesions were mixed osteolytic and osteoblastic, and most (69.8%) patients presented with multiple BMs. The median survival after BMs diagnosis was 11 months. In multivariate analyses, survival after BM diagnosis was correlated with Karnofsky performance status (P=0.008) and the Child-Pugh classification(P&lt;0.001); BM-free survival was correlated with progression beyond the University of California San Francisco criteria(P&lt;0.001) and treatment of primary tumors (P&lt;0.001).</description><identifier>ISSN: 1499-3872</identifier><identifier>DOI: 10.1016/S1499-3872(16)60173-X</identifier><identifier>PMID: 28992882</identifier><language>eng</language><publisher>Singapore: Elsevier B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; bone metastases ; Bone Neoplasms - mortality ; Bone Neoplasms - secondary ; Bone Neoplasms - therapy ; Carcinoma, Hepatocellular - pathology ; carcinoma;bone ; factors ; Female ; hepatocellular ; hepatocellular carcinoma ; Humans ; Liver Neoplasms - pathology ; Male ; metastases;survival;prognostic ; Middle Aged ; Prognosis ; prognostic factors ; survival</subject><ispartof>Hepatobiliary & pancreatic diseases international, 2017-10, Vol.16 (5), p.499-505</ispartof><rights>2017 The Editorial Board of Hepatobiliary & Pancreatic Diseases International</rights><rights>Copyright © 2017 The Editorial Board of Hepatobiliary & Pancreatic Diseases International. Published by Elsevier B.V. All rights reserved.</rights><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c547t-40642349657a483eb3b162f0a5a9fc63561bc4926db358336aa40fd213fa6fd03</citedby><cites>FETCH-LOGICAL-c547t-40642349657a483eb3b162f0a5a9fc63561bc4926db358336aa40fd213fa6fd03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/89801X/89801X.jpg</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1499-3872(16)60173-X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28992882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Yang</creatorcontrib><creatorcontrib>Hu, Jin-Gen</creatorcontrib><creatorcontrib>Lin, Xiang-Jin</creatorcontrib><creatorcontrib>Li, Xi-Gong</creatorcontrib><title>Bone metastases from hepatocellular carcinoma:clinical features and prognostic factors</title><title>Hepatobiliary & pancreatic diseases international</title><addtitle>Hepatobiliary & Pancreatic Diseases International</addtitle><description>BACKGROUND: Bone metastases (BMs) from hepatocellular carcinoma (HCC) is an increasingly common disease in Asia. We assessed the clinical features, prognostic factors, and differences in outcomes related to BMs among patients with different treatments for HCC.METHODS: Forty-three consecutive patients who were diagnosed with BMs from HCC between January 2010 and December2014 were retrospectively enrolled. The clinical features were identified, the impacts of prognostic factors on survival were statistically analyzed, and clinical data were compared.RESULTS: The median patient age was 54 years; 38 patients were male and 5 female. The most common site for BMs was the trunk (69.3%). BMs with extension to the soft tissue were found in 14 patients (32.5%). Most (90.7%) of the lesions were mixed osteolytic and osteoblastic, and most (69.8%) patients presented with multiple BMs. The median survival after BMs diagnosis was 11 months. In multivariate analyses, survival after BM diagnosis was correlated with Karnofsky performance status (P=0.008) and the Child-Pugh classification(P&lt;0.001); BM-free survival was correlated with progression beyond the University of California San Francisco criteria(P&lt;0.001) and treatment of primary tumors (P&lt;0.001).</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>bone metastases</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - secondary</subject><subject>Bone Neoplasms - therapy</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>carcinoma;bone</subject><subject>factors</subject><subject>Female</subject><subject>hepatocellular</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>metastases;survival;prognostic</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>survival</subject><issn>1499-3872</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9P3DAQxX1oBZT2I7SK1AsIpfh_kl4QoBaQkDjQVtysiWMHrxJ7sRMQ--nxsgvXSpbssd7Me_ND6CvBPwgm8viW8KYpWV3RAyIPJSYVK-8-oL337130KaUFxrSuhdxBu7Rumvyme-jfWfCmGM0EKR-TChvDWNybJUxBm2GYB4iFhqidDyP81IPzTsNQWAPTHLMefFcsY-h9SJPThQU9hZg-o48WhmS-bO999Pf3rz_nl-X1zcXV-el1qQWvppJjySnjjRQV8JqZlrVEUotBQGO1ZEKSVvOGyq5lomZMAnBsO0qYBWk7zPbR0WbuE3gLvleLMEefHVW_6LvndrVSK5p5YIFxldUHG3UO_DCbNKnRpfWW4E2YkyJNjpLd6vVgsZHqGFKKxqpldCPEZ0WwWkNXr9DVmq7K1St0dZf7vm0t5nY03XvXG_EsONkITMby6ExUSTvjtelcNHpSXXD_tfi-jXYffP_g8tZvLhXGmFEuBGEvW32f9g</recordid><startdate>20171015</startdate><enddate>20171015</enddate><creator>Lu, Yang</creator><creator>Hu, Jin-Gen</creator><creator>Lin, Xiang-Jin</creator><creator>Li, Xi-Gong</creator><general>Elsevier B.V</general><general>Department of Orthopedics, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>20171015</creationdate><title>Bone metastases from hepatocellular carcinoma:clinical features and prognostic factors</title><author>Lu, Yang ; Hu, Jin-Gen ; Lin, Xiang-Jin ; Li, Xi-Gong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c547t-40642349657a483eb3b162f0a5a9fc63561bc4926db358336aa40fd213fa6fd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>bone metastases</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - secondary</topic><topic>Bone Neoplasms - therapy</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>carcinoma;bone</topic><topic>factors</topic><topic>Female</topic><topic>hepatocellular</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>metastases;survival;prognostic</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Yang</creatorcontrib><creatorcontrib>Hu, Jin-Gen</creatorcontrib><creatorcontrib>Lin, Xiang-Jin</creatorcontrib><creatorcontrib>Li, Xi-Gong</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Hepatobiliary & pancreatic diseases international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Yang</au><au>Hu, Jin-Gen</au><au>Lin, Xiang-Jin</au><au>Li, Xi-Gong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone metastases from hepatocellular carcinoma:clinical features and prognostic factors</atitle><jtitle>Hepatobiliary & pancreatic diseases international</jtitle><addtitle>Hepatobiliary & Pancreatic Diseases International</addtitle><date>2017-10-15</date><risdate>2017</risdate><volume>16</volume><issue>5</issue><spage>499</spage><epage>505</epage><pages>499-505</pages><issn>1499-3872</issn><abstract>BACKGROUND: Bone metastases (BMs) from hepatocellular carcinoma (HCC) is an increasingly common disease in Asia. We assessed the clinical features, prognostic factors, and differences in outcomes related to BMs among patients with different treatments for HCC.METHODS: Forty-three consecutive patients who were diagnosed with BMs from HCC between January 2010 and December2014 were retrospectively enrolled. The clinical features were identified, the impacts of prognostic factors on survival were statistically analyzed, and clinical data were compared.RESULTS: The median patient age was 54 years; 38 patients were male and 5 female. The most common site for BMs was the trunk (69.3%). BMs with extension to the soft tissue were found in 14 patients (32.5%). Most (90.7%) of the lesions were mixed osteolytic and osteoblastic, and most (69.8%) patients presented with multiple BMs. The median survival after BMs diagnosis was 11 months. In multivariate analyses, survival after BM diagnosis was correlated with Karnofsky performance status (P=0.008) and the Child-Pugh classification(P&lt;0.001); BM-free survival was correlated with progression beyond the University of California San Francisco criteria(P&lt;0.001) and treatment of primary tumors (P&lt;0.001).</abstract><cop>Singapore</cop><pub>Elsevier B.V</pub><pmid>28992882</pmid><doi>10.1016/S1499-3872(16)60173-X</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1499-3872 |
| ispartof | Hepatobiliary & pancreatic diseases international, 2017-10, Vol.16 (5), p.499-505 |
| issn | 1499-3872 |
| language | eng |
| recordid | cdi_wanfang_journals_gjgdybzz_z201705007 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over bone metastases Bone Neoplasms - mortality Bone Neoplasms - secondary Bone Neoplasms - therapy Carcinoma, Hepatocellular - pathology carcinoma bone factors Female hepatocellular hepatocellular carcinoma Humans Liver Neoplasms - pathology Male metastases survival prognostic Middle Aged Prognosis prognostic factors survival |
| title | Bone metastases from hepatocellular carcinoma:clinical features and prognostic factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A52%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20metastases%20from%20hepatocellular%20carcinoma:clinical%20features%20and%20prognostic%20factors&rft.jtitle=Hepatobiliary%20&%20pancreatic%20diseases%20international&rft.au=Lu,%20Yang&rft.date=2017-10-15&rft.volume=16&rft.issue=5&rft.spage=499&rft.epage=505&rft.pages=499-505&rft.issn=1499-3872&rft_id=info:doi/10.1016/S1499-3872(16)60173-X&rft_dat=%3Cwanfang_jour_proqu%3Egjgdybzz_z201705007%3C/wanfang_jour_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1949692680&rft_id=info:pmid/28992882&rft_cqvip_id=7000324551&rft_wanfj_id=gjgdybzz_z201705007&rft_els_id=S149938721660173X&rfr_iscdi=true |